Insulet Company Profile (NASDAQ:PODD)

About Insulet (NASDAQ:PODD)

Insulet logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:PODD
  • CUSIP: 45784P10
  • Web:
  • Market Cap: $2.43 billion
  • Outstanding Shares: 57,916,000
Average Prices:
  • 50 Day Moving Avg: $41.80
  • 200 Day Moving Avg: $40.79
  • 52 Week Range: $27.62 - $48.23
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -840.60
  • P/E Growth: -3.46
Sales & Book Value:
  • Annual Revenue: $387.49 million
  • Price / Sales: 6.28
  • Book Value: $1.10 per share
  • Price / Book: 38.21
  • EBIDTA: $11.22 million
  • Net Margins: -12.95%
  • Return on Equity: -87.46%
  • Return on Assets: -10.74%
  • Debt-to-Equity Ratio: 5.05%
  • Current Ratio: 6.67%
  • Quick Ratio: 6.07%
  • Average Volume: 495,113 shs.
  • Beta: 1.42
  • Short Ratio: 7.23

Frequently Asked Questions for Insulet (NASDAQ:PODD)

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its earnings results on Monday, May, 8th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The company had revenue of $101.70 million for the quarter, compared to analysts' expectations of $97.73 million. Insulet had a negative net margin of 12.95% and a negative return on equity of 87.46%. The business's revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) earnings per share. View Insulet's Earnings History.

Where is Insulet's stock going? Where will Insulet's stock price be in 2017?

12 equities research analysts have issued twelve-month price objectives for Insulet's stock. Their predictions range from $38.00 to $50.00. On average, they expect Insulet's share price to reach $46.00 in the next year. View Analyst Ratings for Insulet.

What are analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:

  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (5/12/2017)
  • 2. Northland Securities analysts commented, "Regulatory Filings Falling into Place. With the FDA BLA formal submission expected next week, Spark has shifted its focus towards its MAA filing for Europe and pre-commercialization activities." (5/9/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet's key competitors?

Who owns Insulet stock?

Insulet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Wellington Management Group LLP (9.65%), Primecap Management Co. CA (8.98%), Vanguard Group Inc. (7.90%), BlackRock Inc. (7.28%) and Valinor Management L.P. (3.19%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet.

Who sold Insulet stock? Who is selling Insulet stock?

Insulet's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Wellington Management Group LLP, Valinor Management L.P., FIL Ltd, Kornitzer Capital Management Inc. KS, JPMorgan Chase & Co., Massachusetts Financial Services Co. MA and Teachers Advisors LLC. Company insiders that have sold Insulet stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet.

Who bought Insulet stock? Who is buying Insulet stock?

Insulet's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Champlain Investment Partners LLC, Frontier Capital Management Co. LLC, Vanguard Group Inc., Nationwide Fund Advisors, Delta Lloyd NV, Geode Capital Management LLC and State Street Corp. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.

How do I buy Insulet stock?

Shares of Insulet can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Insulet stock cost?

One share of Insulet stock can currently be purchased for approximately $42.03.

Analyst Ratings

Consensus Ratings for Insulet (NASDAQ:PODD) (?)
Ratings Breakdown: 5 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $46.00 (9.45% upside)

Analysts' Ratings History for Insulet (NASDAQ:PODD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
5/10/2017Jefferies Group LLCLower Price TargetBuy$53.00 -> $48.00MediumView Rating Details
5/10/2017BTIG ResearchUpgradeNeutral -> Buy$47.00MediumView Rating Details
5/9/2017Oppenheimer Holdings Inc.Set Price TargetHold$46.00HighView Rating Details
5/9/2017Northland SecuritiesReiterated RatingBuy$50.00HighView Rating Details
2/28/2017WedbushBoost Price TargetOutperform -> Outperform$48.00 -> $50.00N/AView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
2/13/2017Canaccord GenuityReiterated RatingHold$39.00N/AView Rating Details
1/6/2017Robert W. BairdUpgradeNeutral -> Outperform$39.00 -> $47.00N/AView Rating Details
11/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/AView Rating Details
11/7/2016Leerink SwannReiterated RatingOutperform$55.00 -> $50.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
4/29/2016William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00N/AView Rating Details
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Insulet (NASDAQ:PODD)
Earnings by Quarter for Insulet (NASDAQ:PODD)
Earnings History by Quarter for Insulet (NASDAQ:PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insulet (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20178($0.23)($0.10)($0.15)
Q2 20178($0.16)($0.04)($0.12)
Q3 20178($0.13)($0.02)($0.09)
Q4 20178($0.11)($0.02)($0.09)
Q1 20184($0.11)$0.02($0.05)
Q2 20184($0.11)$0.05($0.02)
Q3 20184($0.10)$0.06$0.00
Q4 20184($0.09)$0.06($0.01)
(Data provided by Zacks Investment Research)


Dividend History for Insulet (NASDAQ:PODD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insulet (NASDAQ:PODD)
Insider Ownership Percentage: 1.90%
Insider Trades by Quarter for Insulet (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)
Insider Trades by Quarter for Insulet (NASDAQ:PODD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insulet (NASDAQ:PODD)
Latest Headlines for Insulet (NASDAQ:PODD)
DateHeadline logoInsulet Co. (PODD) Research Coverage Started at Piper Jaffray Companies - May 22 at 10:20 AM logoINSULET INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Insulet Corporation for Possible Securities Fraud - May 20 at 9:53 AM logoMichael P. Spears Purchases 2,500 Shares of Insulet Co. (PODD) Stock - May 18 at 10:16 AM logoUpdate in Lawsuit for Investors in NASDAQ: PODD Shares Against Insulet Corporation Announced by Shareholders Foundation - May 17 at 7:12 PM logoInsulet Co. (PODD) Stock Rating Upgraded by BTIG Research - May 14 at 5:14 PM logoInsulet's (PODD) "Neutral" Rating Reiterated at B. Riley - May 14 at 10:16 AM logoInsulet Co. (PODD) Rating Increased to Hold at Zacks Investment Research - May 13 at 12:44 PM logoZacks: Brokerages Expect Insulet Co. (PODD) Will Announce Quarterly Sales of $106.07 Million - May 13 at 8:24 AM logoInsulet Co. (PODD) Receives Average Recommendation of "Buy" from Brokerages - May 13 at 12:46 AM logoInsulet Co. (PODD) Director Purchases $99,794.40 in Stock - May 12 at 10:17 AM logoInsulet Co. (PODD) EVP Purchases $116,070.00 in Stock - May 12 at 10:16 AM logoNorthcoast Research Weighs in on Insulet Co.'s Q2 2017 Earnings (PODD) - May 12 at 8:50 AM logo-$0.12 EPS Expected for Insulet Co. (PODD) This Quarter - May 11 at 2:14 PM logoInsulet Co. to Post Q1 2018 Earnings of ($0.04) Per Share, Northcoast Research Forecasts (PODD) - May 11 at 1:30 PM logoLeerink Swann Equities Analysts Cut Earnings Estimates for Insulet Co. (PODD) - May 11 at 11:08 AM logoFY2017 EPS Estimates for Insulet Co. Boosted by Analyst (PODD) - May 11 at 10:54 AM logoQ2 2017 Earnings Forecast for Insulet Co. Issued By Jefferies Group (PODD) - May 11 at 7:54 AM logoOppenheimer Holdings Comments on Insulet Co.'s Q2 2017 Earnings (PODD) - May 11 at 7:54 AM logoB. Riley Analysts Cut Earnings Estimates for Insulet Co. (PODD) - May 11 at 7:54 AM logoInsulet Co. to Post FY2019 Earnings of ($0.06) Per Share, Wedbush Forecasts (PODD) - May 10 at 2:54 PM logoQ1 2018 EPS Estimates for Insulet Co. Reduced by Leerink Swann (PODD) - May 10 at 1:02 PM logoBTIG Upgrades Insulet Corporation (PODD) to Buy, Buying On Weakness Following Strong Quarter - May 10 at 11:35 AM logoEdited Transcript of PODD earnings conference call or presentation 8-May-17 8:30pm GMT - May 10 at 11:35 AM logoInsulet Co. (PODD) Rating Reiterated by Jefferies Group LLC - May 10 at 9:59 AM logoOppenheimer Holdings Inc. Analysts Give Insulet Co. (PODD) a $46.00 Price Target - May 9 at 11:02 PM logoInsulet (PODD) Q1 2017 Results - Earnings Call Transcript - May 9 at 6:50 PM logoInsulet Co. (PODD) Posts Earnings Results, Misses Expectations By $0.01 EPS - May 9 at 11:48 AM logoInsulet Co. (PODD) Stock Rating Reaffirmed by Northland Securities - May 9 at 11:32 AM logoInsulet Pumps Out 25% Revenue Growth, Edges Up 2017 Guidance - May 9 at 11:25 AM logoInsulet Reports First Quarter 2017 Financial Results - May 9 at 11:03 AM logoINSULET INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Insulet Corporation for Possible Securities Fraud - PODD - May 9 at 11:03 AM logoInsulet reports 1Q loss - May 8 at 4:13 PM logoInvestor Network: Insulet Corporation to Host Earnings Call - May 8 at 11:58 AM logoRobbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Class Action - May 3 at 7:43 PM logoDavid A. Lemoine Sells 1,524 Shares of Insulet Co. (PODD) Stock - May 2 at 10:22 PM logoInsulet (PODD) Receives Daily News Sentiment Rating of -0.12 - April 29 at 8:23 AM logoFirst Week of December 15th Options Trading For Insulet (PODD) - April 28 at 8:16 PM logoInsulet Corp. – Value Analysis (NASDAQ:PODD) : April 28, 2017 - April 28 at 8:16 PM logoInsulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : April 27, 2017 - April 27 at 10:33 AM logoInsulet (PODD) Getting Somewhat Critical Press Coverage, Analysis Shows - April 26 at 1:22 PM logoInsulet (PODD) Given Media Impact Rating of -0.10 - April 23 at 3:34 PM logoInsulet Co. (PODD) Expected to Announce Quarterly Sales of $98.09 Million - April 22 at 7:51 AM logoInsulet Co. (PODD) Expected to Post Earnings of -$0.15 Per Share - April 20 at 8:27 PM logoInsulet Enters Oversold Territory (PODD) - April 18 at 6:35 PM logoSomewhat Positive News Coverage Likely to Affect Insulet (PODD) Share Price - April 18 at 12:57 AM logoInsulet Co. (PODD) Given Average Rating of "Hold" by Brokerages - April 18 at 12:53 AM logoInsulet (PODD) Receives Coverage Optimism Rating of 0.36 - April 14 at 11:53 PM logo​Medical device firm Insulet opening manufacturing site in Acton - April 10 at 6:49 PM logoInsulet Corporation to Announce First Quarter 2017 Financial Results on May 8, 2017 - April 7 at 7:38 PM logoETFs with exposure to Insulet Corp. : April 7, 2017 - April 7 at 7:38 PM



Insulet (PODD) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff